Acadia Pharmaceuticals | ACAD - Market Capitalization


Acadia Pharmaceuticals reported $4.11B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.6B 10M Sep/2025
ALKERMES USD 5.65B 696M Feb/2026
Alnylam Pharmaceuticals USD 39.74B 12.8B Feb/2026
Biogen USD 27.01B 1.19B Feb/2026
BioMarin Pharmaceutical USD 11.99B 575M Feb/2026
Bristol-Myers Squibb USD 123.58B 13.77B Feb/2026
Cara Therapeutics USD 46M 23M Jun/2025
Corcept Therapeutics USD 3.7B 5.05B Feb/2026
Cytokinetics USD 8.06B 1.49B Feb/2026
Eisai JPY 1.43T 119.2B Feb/2026
Eli Lilly USD 1.01T 3.37B Feb/2026
Incyte USD 22.7B 3.31B Feb/2026
J&J USD 500.24B 67.44B Dec/2025
Moderna USD 16.5B 6.41B Feb/2026
Neurocrine Biosciences USD 13.68B 465M Feb/2026
Pfizer USD 152.89B 11.32B Feb/2026
Prothena USD 473M 52M Feb/2026
PTC Therapeutics USD 5.36B 744M Feb/2026
Sarepta Therapeutics USD 2.02B 336M Sep/2025
Ultragenyx Pharmaceutical USD 1.94B 284M Feb/2026
Vanda Pharmaceuticals USD 243M 136M Dec/2023
Vertex Pharmaceuticals USD 120.12B 5.09B Feb/2026